Compare Deere & Company (DE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Viatris Inc — how do they compare? Deere & Company trades at $584.4 (market cap $157.75B), while Viatris Inc trades at $16.26 (market cap $18.99B). The key difference: Deere & Company is far larger — about 8.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.94%). Which is the better fit depends on your goals.
| DE | VTRS | |
|---|---|---|
Market Cap | $157.75B | $18.99B |
Sector | Industrials | Health |
52-Week High | $662.49 | $17.39 |
52-Week Low | $439.11 | $8.74 |
Enterprise Value | $212.58B | $31.20B |
Dividend Yield | 1.11% | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $585.64, down 0.21% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue declined to $44.67B in 2025, though net income margin remains solid at 10.33%. Recent news highlights a $20B precision agriculture initiative and regulatory agreements enhancing farmer access to repair tools.
The outlook is mixed: analyst consensus targets $676.08 (15% upside) with 41% buy ratings, but technicals and declining revenue pose near-term risks. Key opportunities include margin strength and agtech growth; risks involve cyclical farming demand and high debt levels. Investors should weigh fundamental resilience against sector headwinds.
Viatris (VTRS) trades at $16.39, up 0.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, with improving cash flow trends and a consensus price target of $20. Recent positive Phase 3 results for VR-205 and FDA acceptance of a new drug application highlight pipeline progress.
The outlook is mixed: strong analyst buy ratings and a 22% upside to target suggest value, but profitability challenges and high debt pose risks. Investors should weigh the potential from pipeline catalysts against ongoing margin pressure and competitive threats in the generic drug space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
